Calliditas Therapeutics: Our Comment on the Capital Raise
Research Note
2020-06-23
07:20
Redeye maintains its positive view and Base case of SEK 140 following Calliditas’ US IPO and concurrent private placement.
LS
Ludvig Svensson
Disclosures and disclaimers